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The Journal of Immunology
Placental Growth Factor-1 and -2 Induce Hyperplasia and
Invasiveness of Primary Rheumatoid Synoviocytes
Seung-Ah Yoo,* Ji-Hwan Park,† Seong-Hye Hwang,* Sang-Min Oh,* Saseong Lee,*
Valeria Cicatiello,‡,x Sangchul Rho,{ Sandro De Falco,‡,‖ Daehee Hwang,‖,#
Chul-Soo Cho,*,** and Wan-Uk Kim*,**
Inflammation-mediated oncogenesis has been implicated in a variety of cancer types. Rheumatoid synovial tissues can be viewed as
a tumor-like mass, consisting of hyperplastic fibroblast-like synoviocytes (FLSs). FLSs of rheumatoid arthritis (RA) patients have
promigratory and invasive characteristics, which may be caused by chronic exposure to genotoxic stimuli, including hypoxia and
growth factors. We tested whether a transformed phenotype of RA-FLSs is associated with placental growth factor (PlGF), a rep-
resentative angiogenic growth factor induced by hypoxia. In this study, we identified PlGF-1 and PlGF-2 as the major PlGF
isoforms in RA-FLSs. Global gene expression profiling revealed that cell proliferation, apoptosis, angiogenesis, and cell migration
were mainly represented by differentially expressed genes in RA-FLSs transfected with small interfering RNA for PlGF. Indeed,
PlGF-deficient RA-FLSs showed a decrease in cell proliferation, migration, and invasion, but an increase in apoptotic death
in vitro. PlGF gene overexpression resulted in the opposite effects. Moreover, exogeneous PlGF-1 and PlGF-2 increased survival,
migration, and invasiveness of RA-FLSs by binding their receptors, Flt-1 and neuropilin-1, and upregulating the expression of
antiapoptotic molecules, pErk and Bcl2. Knockdown of PlGF transcripts reduced RA-FLS proliferation in a xenotransplantation
model. Collectively, in addition to their role for neovascularization, PlGF-1 and -2 promote proliferation, survival, migration, and
invasion of RA-FLSs in an autocrine and paracrine manner. These results demonstrated how primary cells of mesenchymal origin
acquired an aggressive and transformed phenotype. PlGF and its receptors thus offer new targets for anti-FLS therapy. The
Journal of Immunology, 2015, 194: 2513–2521.
R
heumatoid arthritis (RA) is characterized by tumor-like
expansion of the synovium, angiogenesis, and destruc-
tion of adjacent articular cartilage and bone (1, 2).Various
cell populations, including innate immune cells, adaptive immune
cells, endothelial cells, and fibroblast-like synoviocytes (FLSs),
are activated in RA joints (3). FLSs in particular represent a major
effector in the invasive pannus, directly participating in chronic
inflammation and joint destruction (4). They produce high levels
of matrix metalloproteinases, proinflammatory cytokines, such as
IL-1 and IL-6 (3, 5), and angiogenic factors, including vascular
endothelial growth factor (VEGF) and placental growth factor
(PlGF) (6, 7). Moreover, although RA-FLSs are primary cells,
they proliferate abnormally and exhibit characteristics of meta-
static cancer cells, represented by somatic mutations of H-Ras and
p53 genes (8, 9). Besides abnormal proliferation, RA-FLSs also
show invasiveness and excessive migratory capacity (10, 11), al-
though the mechanisms involved are not fully understood. Despite
the importance of FLS in RA pathogenesis, there have been no
trials to specifically suppress FLS proliferation and invasiveness.
PlGF, originally identified in the placenta, is a member of the
VEGF family (12, 13). The human PlGF gene encodes four dif-
ferent isoforms, that is, PlGF-1 (131 aa), PlGF-2 (152 aa), PlGF-3
(203 aa), and PlGF-4 (224 aa), as a result of alternative splicing,
whereas mice only express PlGF-2 (12, 13). Unlike VEGF, which
binds to VEGFR-1 (Flt-1) and VEGFR-2, PlGF selectively binds
VEGFR-1 and its coreceptors neuropilin (NP)-1 and -2 (12). PlGF
has potent angiogenic activities via Flt-1, and it directly mediates
chronic inflammation by stimulating leukocyte infiltration (14–
16). Furthermore, PlGF regulates the migration and survival of
myeloid and endothelial cells (12, 14, 17). PlGF is also expressed
in various cell types, including hematopoietic cells, keratinocytes,
and bronchial epithelial cells, and it plays a critical role in tumor
growth, invasion, and metastasis in some types of cancer (12, 14).
Chronic inflammation has been implicated in tumorigenesis (18–
21). Inflammation-mediated oncogenesis is found in a variety of
cancers, including skin, lung, bladder, stomach, and liver cancer
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(18). Although the exact mechanism is still unclear, some growth
factors and proinflammatory cytokines play an important role. For
example, mice deficient in TNF-a are resistant to skin carcino-
genesis (19). Host-derived IL-1 is required for tumor invasive-
ness and angiogenesis. Constitutive expression of platelet-derived
growth factor-BB can lead to malignant transformation of hu-
man cells (20). Sustained JNK1 activation enhances chemical
hepatocarcinogenesis (21). Taken together, it appears that under
pathological conditions, chronic exposure to proinflammatory
cytokines and growth factors may convert host primary cells to
a transformed phenotype.
PlGF, an angiogenic growth factor, is frequently found at high
concentrations in RA joints (6). We postulated that a transformed
and aggressive phenotype of primary RA-FLSs may be caused by
chronic exposure to proinflammatory cytokines and growth fac-
tors, including PlGF. We first demonstrated that PlGF-1 and -2
were critical for proliferation and invasiveness of primary rheu-
matoid synoviocytes. PlGF-deficient RA-FLSs showed a decrease
in cell proliferation, migration, and invasion, but an increase in
apoptotic death. Conversely, exogeneous PlGF-1 and PlGF-2 in-
creased survival, migration, and invasiveness of RA-FLSs by
binding their receptors, Flt-1 and NP-1, and upregulated the ex-
pression of antiapoptotic molecules, pErk and Bcl2. Collectively,
our data indicate that PlGF-1 and -2 promote proliferation, sur-
vival, migration, and invasion of primary rheumatoid cells, and
thus could be a potential target for anti-FLS therapy.
Materials and Methods
Isolation and culture of synoviocytes
FLSs were prepared from the synovial tissues of RA patients as de-
scribed previously (22) and incubated in DMEM supplemented with
10% FBS.
Microarray experiments
Total RNA was isolated from RA-FLSs 12 h after PlGF small interfering
RNA (siRNA) or control siRNA treatment. RNA integrity was evaluated
by a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). The RNA
integrity number in all samples was .9.5. Following the standard Agilent
protocols, RNA was reverse-transcribed, amplified, and then hybridized
onto the Agilent SurePrint G3 human gene expression 8 3 60K v2
microarray containing 62,976 probes for 23,284 annotated genes. The data
were deposited in the Gene Expression Omnibus database (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64922) under accession no.
GSE64922.
Overexpression of PlGF-2 gene in SV40-immortalized
RA-FLSs
The PlGF plasmid DNA tagged with pCDNA3 (24 mg) was transfected
into SV40-immortalized RA-FLSs by Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Three to four weeks after transfection, stable expression of
PlGF-2 in transfected cells was screened by ELISA, and bulk populations of
cells harboring PlGF constructs tagged with pCDNA3 were selected. The
cells were subsequently maintained in 0.5 mg/ml G418 (Life Technologies,
Gaithersburg, MD).
Knockdown of PlGF and PlGF receptor transcripts
RA-FLSs were transfected with PlGF siRNA, Flt-1 siRNA, or NP-1 siRNA
(Santa Cruz Biotechnology, Santa Cruz, CA) using Lipofectamine 2000
(22).
Real-time PCR
Total RNAwas isolated from RA-FLSs using an RNeasy Mini kit (Qiagen,
Hilden, Germany), according to the manufacturer’s instructions. Real-time
PCR was performed in the CFX96 real-time PCR system (Bio-Rad, Her-
cules, CA) using SYBR Premix (Bio-Rad). Transcript levels were calcu-
lated relative to controls, and relative fold inductions were calculated by
using the 22DDCt algorithm. The following primers were used for ampli-
fication (forward, reverse): E2F2, 59-GGTGAGCTGAAGAACCTTGC-39
and 59-GCCCAGAGCTGCAGTTTAAT-39; CDK1, 59-TTTTCAGAGCT-
TTGGGCACT-39 and 59-AAATTCGTTTGGCTGGATCA-39; CASP1, 59-
GCTTTCTGCTCTTCCACACC-39 and 59-CATCTGCGCTCTACCATC-
TG-39; CASP7, 59-GGCAAAGATTTTTGGCACTT-39 and 59-TGGTTA-
GGAATTAAGCAACCACA-39; BCL2, 59-TTTACCTTCCATGGCTCT-
TTTT-39 and 59-GGCAATGTGACTTTTTCCAA-39; NANOS1, 59-
CAGTATTAATTTGGGCGGGTA-39 and 59-AAGGTGGAAAAGGCTA-
GTTGC-39; KIT, 59-ACTTCAGGGGCACTTCATTG-39 and 59-GACT-
CATGGGCTTGGGAATA-39; CCL28, 59-GGGAAACACGAAACATAC-
GG-39 and 59-TTGGCTACATTTGCATACCG-39; PlGF-1, 59-CTGCGA-
ATGCCGGCCTCT-39 and 59-GCACCTTTCCGGCTTCAT-39; PlGF-2,
59-CTGCGAATGCCGGCCTCT-39 and 59-TGTGGGTCTCTGCTTCTC-
TCT-39; PlGF-3, 59-GGCTGATGCTCCCTCCTT-39 and 59-GCACCTTT-
CCGGCTTCAT-39; PlGF-4, 59-GGCTGATGCTCCCTCCTT-39 and 59-
TGTGGGTCTCTGCTTCTCTCT-39; GAPDH, 59-TGATGACATCAA-
GAAGGTGG-39 and 59-TTTCTTACTCCTTGGAGGCC-39.
PlGF-1– and PlGF-2–conditioned media preparation
HEK-293 stable clones overexpressing human PlGF-1 or human PlGF-2
were obtained as previously described (23). A stable clone obtained af-
ter transfection of empty pCDNA3 vector was used as control. Serum-
free–conditioned media were collected form semiconfluent cultured cells
and concentrated on a Centricon (Sartorius) with a 10,000 Da molecular
mass cutoff. The concentration of PlGF-1 and PlGF-2 was determined by
sandwich ELISAs, as previously described (23).
ELISA for PlGF
The PlGF concentrations were also measured in the culture supernatants
using an ELISA kit (R&D Systems, Minneapolis, MN).
Immunofluorescence staining
RA synovium was fixed with cold acetone for 10 min at220˚C and blocked
with 1% BSA for 30 min. Tissue sections were then incubated with goat
anti-PlGF Abs (1:100; Santa Cruz Biotechnology) plus mouse anti-CD55
Abs (1:200; Santa Cruz Biotechnology) or with goat anti-PlGFAbs (1:100;
Santa Cruz Biotechnology) plus mouse anti-CD68 Abs (1:50; Santa Cruz
Biotechnology) overnight at 4˚C. Each slide was washed three times in
PBS and incubated with Cy3-conjugated anti-goat IgG and Alexa Fluor
488–conjugated anti-mouse IgG (Invitrogen). After washing in PBS, the
coverslips were mounted on glass slides with ProLong antifade solution
(Invitrogen).
Cell proliferation assay
FLS proliferation rate after PlGF siRNA transfection was determined using
a BrdU proliferation assay kit according to the manufacturer’s instructions.
Manual cell counts were performed by trypan blue exclusion to identify
viable cells.
Determination of cell viability
The viability of FLSs was determined by an MTT assay as described
previously (22).
Detection of apoptosis
FLS apoptosis was determined using the APOPercentage apoptosis assay
kit (24). Digital images of APOPercentage dye-labeled cells, which ap-
pear bright pink against a white background under a light microscope,
were used to quantify apoptotic cell numbers. FLS apoptosis levels were
expressed as a pixel number.
Western blot analysis
FLSs were lysed in a lysis buffer, and insoluble material was removed by
centrifugation at 14,000 rpm for 20 min at 4˚C. Final protein concentrations
were determined using the Bradford protein assay. Electrophoresis was
performed using SDS-PAGE, and blots were transferred to nitrocellulose
membranes. Membranes were incubated with Abs to PlGF (Santa Cruz
Biotechnology), Bcl2 (Santa Cruz Biotechnology), Bax (Santa Cruz Bio-
technology), pErk (Cell Signaling Technology, Beverly, MA), Erk (Cell
Signaling Technology), pAkt (Cell Signaling Technology), Akt (Cell
Signaling Technology), and b-actin (Sigma-Aldrich). Membranes were
then visualized using an enhanced chemiluminescent technique.
Wound migration assay
The wound migration of RA-FLSs was measured as described previously
(25). In brief, FLSs plated to confluence on a six-well plate were wounded
with pipette tips and then treated with IL-1b or PlGF in DMEM supple-
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mented with 1% FBS. After 12 h of incubation, FLS migration was
quantified by counting the cells that had moved beyond a reference line.
The migration of PlGF-deficient RA-FLSs was assessed in some experi-
ments after 24 h of transfection with PlGF siRNA.
Matrigel invasion assay
The BD BioCoat Matrigel invasion chamber assay system (Becton Dick-
inson, Heidelberg, Germany) was used to evaluate FLS invasion, according
to the manufacturer’s instructions (25). Briefly, 24 h after transfection with
siRNA, RA-FLSs were allowed to migrate in a Matrigel layer chamber for
an additional 12 h in the presence of DMEM containing 10% FBS or 10
ng/ml IL-1b in DMEM supplemented with 1% FBS. In some experiments,
medium supplemented with PlGF was used as an attractant in the lower
chamber. The noninvading cells were subsequently removed by scrubbing
with a cotton-tipped swab, and the cells on the lower surface of the
membrane were stained with Diff-Quik stain (Baxter Diagnostics, McGaw
Park, IL). For quantification, cells were manually counted in eight random
fields.
Determination of FLS proliferation in vivo
RA-FLSs (5 3 105) were transfected with control or PlGF siRNA for 24 h
and then mixed with 500 ml Matrigel (Becton Dickinson). The Matrigel
containing RA-FLSs was injected s.c. into the abdomen of athymic nude
mice (The Jackson Laboratory, Bar Harbor, ME), as previously described
(26). After 7 d, the skin containing the Matrigel plugs was excised and
snap-frozen. Sections were stained with anti-human HLA class I Ab and
analyzed by confocal microscopy (Zeiss LSM 510; Carl Zeiss, Thorn-
wood, NJ). The number of HLA class I+ cells, indicating RA-FLSs, was
determined by counting the number of positively stained cells.
Statistical analysis
For the analysis of gene expression data, log2 intensities in individual
samples were first normalized using the quantile normalization method
(27). An integrative statistical method previously described (28) was ap-
plied to the normalized intensities to identify differentially expressed genes
(DEGs). Briefly, for each gene a Student t test and log2 median ratio test
were applied, resulting in T values and log2 median ratios between RA-
FLSs treated with PlGF and control siRNAs. Empirical null distributions
for T values and log2 median ratios were estimated by applying the
Gaussian kernel density estimation method (29) to T values and log2
median ratios obtained from 1000 random permutations of the samples.
For each gene, adjusted p values of the two tests were calculated by two-
tailed tests for the observed T value and log2 median ratio using the em-
pirical distributions, and p values of the two tests were then combined to an
overall p value by using Stouffer’s method (30). The DEGs were identified
as genes with overall p values , 0.05 and absolute log2 fold change . the
mean of the 2.5th and 97.5th percentiles of the empirical distribution for
the log2 median ratio. Gene ontology biological process (GOBP) enrich-
ment analysis of the DEGs was conducted using DAVID software (31).
Cellular processes represented by the DEGs were identified as the GOBPs
and Kyoto encyclopedia of genes and genomes (KEGG) pathways with
p , 0.1 computed from DAVID.
Data from the in vivo and in vitro functional experiments were expressed
as the mean 6 SD or SEM (SEM). Comparisons of the numerical data
between groups were performed by the paired or unpaired Mann–Whitney
U test. A p value ,0.05 was considered statistically significant.
Results
PlGF isoforms in FLS and their role in FLS biology
We first performed immunofluorescence staining of the synovium
of RA patients to investigate the distribution and localization of
PlGF in joint tissues. The cellular origins of the synovial tissues
were examined by double staining for PlGF and CD55, a specific
marker for FLSs (10). We found that PlGF-expressing cells in the
lining layer were also positive for CD55, indicating that FLSs
were the major source of PlGF production (Fig. 1A). However, as
a control, CD68+ cells, which indicate synovial macrophages,
were not colocalized with PlGF+ cells (Fig. 1A). Alternative
splicing of the primary PlGF transcript generates four different
isoforms of PlGF, that is, PlGF-1, PlGF-2, PlGF-3, and PlGF-4
(12, 13). Among these, PlGF-1 and PlGF-2 are the major iso-
forms to mediate cell growth and migration (12, 14). We next
analyzed the expression of PlGF isoforms in FLSs using real-
time PCR. As a result, PlGF-1 and PlGF-2, but not PlGF-3 and
PlGF-4, were predominantly expressed in RA-FLSs and OA-FLSs
(Fig. 1B and data not shown) and were significantly increased on
IL-1b stimulation. These data indicated that PlGF-1 and PlGF-2
were the major PlGF isoforms expressed in FLSs.
To understand functions of PlGF in RA-FLSs, we next per-
formed gene expression profiling of RA-FLSs treated with PlGF
siRNA and control siRNA. We identified 1732 DEGs (972 up-
regulated and 760 downregulated genes; Supplemental Table I) by
comparing the gene expression profiles. The cellular processes in
which the DEGs are mainly involved were determined by the
functional enrichment analysis of GOBPs and KEGG pathways
using DAVID software (31). The results showed that the DEGs
were mainly involved in cellular processes related to 1) cell pro-
liferation, 2) cell survival or apoptosis, and 3) cell migration (Fig.
1C, Supplemental Fig. 1, Supplemental Table II). Real-time PCR
confirmed differential expression of the following eight repre-
sentative genes related to these processes (Fig. 1D): CDK1 and
E2F2 involving cell proliferation (32); CASP1, CASP7, and BCL2
involving apoptosis; and NANOS1, KIT, and CCL28 involving cell
migration and invasion (33–35). These data indicate that PlGF
may function as a regulator of proliferation, apoptosis, and mi-
gration of RA-FLSs.
PlGF regulation of FLS proliferation
RA-FLSs display similar proliferative properties to cancer cells,
resulting in the formation of a hypertrophic synovial pannus (10).
To validate the effect of PlGF on FLS biology suggested by gene
expression profiling, we first investigated whether PlGF mediates
the proliferation of RA-FLSs in vitro. As shown in Fig. 2A,
TNF-a– or TGF-b–induced increases in BrdU incorporation were
almost completely prevented by PlGF siRNA, but not by control
siRNA. The number of RA-FLSs stimulated with TNF-a or
TGF-b was also completely reduced by PlGF siRNA transfection
(Fig. 2B). Alternatively, overexpression of the PlGF-2 gene in
SV40-immortalized RA-FLSs promoted cell proliferation under
serum-free conditions (Fig. 2C, 2D). These data suggest that PlGF
plays an essential role in FLS proliferation.
To test the PlGF involvement in FLS proliferation in vivo, we s.c.
implanted Matrigel plugs containing RA-FLSs transfected with
PlGF siRNA into immune-deficient mice in the presence of
TGF-b. We have previously shown that TGF-b increases RA-
FLS proliferation in the same in vivo model (26). In the present
study, we first confirmed that the downregulatory effect of PlGF
siRNA persisted to 7 d (Fig. 2E). Immunofluorescence staining
revealed that the number of HLA class I+ cells, indicating RA-
FLSs, was significantly lower in the Matrigels with PlGF siRNA
than in those with control siRNA (Fig. 2F), indicating that PlGF
siRNA inhibited TGF-b–induced FLS proliferation in vivo. We
also found that von Willebrand factor+ cells, indicating neo-
vascularization, were significantly reduced in PlGF siRNA–con-
taining Matrigels than in control Matrigels (Fig. 2G), suggesting
that suppression of FLS proliferation by PlGF siRNA reduces
endothelial cell recruitment to the surroundings of synoviocytes
in vivo.
PlGF control of FLS survival and apoptosis
PlGF can promote survival of macrophages, endothelial cells, and
cancer cells (12, 14, 17). We next investigated whether PlGF
regulates FLS survival. As shown in Fig. 3A, PlGF knockdown
significantly decreased the viability of RA-FLSs in the presence
of sodium nitroprusside (SNP), an apoptosis inducer. On phase-
contrast microscopy, FLSs transfected with PlGF siRNA be-
The Journal of Immunology 2515
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came spherical, shrunken, and detached from the bottom of the
culture plate, whereas control siRNA-transfected cells retained
a bipolar appearance. Furthermore, PlGF knockdown rendered
RA-FLSs more susceptible to serum starvation or SNP-induced
apoptosis, as determined by the APOPercentage apoptosis assay
(Fig. 3B). Conversely, stable overexpression of PlGF-2 gene in-
hibited the SNP-induced death of SV40-immortalized RA-FLSs,
as assessed by the MTT assay (Fig. 3C). Starvation or SNP-
induced FLS apoptosis was also blocked by stable overexpres-
sion of the PlGF-2 gene (Fig. 3D).
The regulation of Bcl2 family members is important to cell
apoptosis and survival (36), which is triggered by serum starvation
and SNP treatment (22). Additionally, the activation of pErk
maintains mitochondrial integrity via upregulation of Bcl2 ex-
pression or via the inhibition of proapoptotic Bcl2 family (22, 36).
Based on our finding on PlGF inhibition of FLS apoptotic death,
we determined whether PlGF regulates the expression of pErk and
Bcl2/Bax in RA-FLSs. As shown in Fig. 3E, downregulation of
PlGF transcripts in RA-FLSs decreased pErk and Bcl2 expression
but increased Bax expression as compared with the control siRNA
transfection. FLSs stably overexpressing the PlGF-2 gene showed
the opposite results, indicating that PlGF controls pErk/Bcl2/Bax
expression in RA-FLSs. Moreover, the protective effect of PlGF-2
overexpression on SNP-induced apoptosis was cancelled by
treating RA-FLSs with the PD98059 Erk inhibitor (Fig. 3F).
Overall, the present findings, together with previous reports (22),
suggest that PlGF regulates FLS survival through a mitochondrial
apoptotic pathway involving Bcl2, Bax, and pErk.
PlGF-dependent FLS survival is mediated by Flt-1 and NP-1
PlGF is primarily derived from FLSs and is detected at high levels
in the synovial fluids of RA patients (6). Thus, we conducted an
experiment to determine the effects of soluble PlGF on FLS sur-
vival. The result showed that conditioned media obtained from
HEK-293 clones overexpressing human PlGF-1 or human PlGF-2
significantly blocked SNP- or starvation-induced apoptosis of
RA-FLSs; however, the addition of anti-PlGF Abs to conditioned
media restored the apoptotic effect evaluated by the APOPer-
centage assay (Fig. 4A, 4B). SNP-induced FLS death, determined
by the MTT assay, was also inhibited by conditioned media
A B
C D
FIGURE 1. PlGF isoform in RA-FLSs and its target gene signatures. (A) Double immunofluorescence staining of PlGF and CD55 in synovial tissues of
RA patient using anti-PlGF and anti-CD55 Abs. Anti-CD68 Abs for synovial macrophages were used as a control. Sections were subsequently stained with
Cy3-conjugated anti-mouse IgG (red) for anti-PlGF Ab and Alexa Fluor 488–conjugated anti-goat IgG (green) for anti-CD55 Ab (or CD68 Ab), re-
spectively. Colocalization of CD55 and PlGF is visualized in yellow on the merged images. The cell nucleus was stained with DAPI. Scale bars, 100 mm.
(B) Quantitative real-time PCR assays for isoforms of PlGF in RA-FLSs in the presence or absence of IL-1b (1 ng/ml). Data are the means 6 SEM of five
different RA-FLSs. *p , 0.05, **p , 0.01 versus unstimulated cells. (C) Functional enrichment analysis for the DEGs in RA-FLSs treated with PlGF
siRNA, as compared with control (scrambled) siRNA. GOBPs and KEGG pathways representing the DEGs were mainly involved in 1) cell proliferation, 2)
cell survival or apoptosis, and 3) cell migration. The bars indicate Z score = N21(1 2 P). (D) Quantitative real-time PCR assay for the eight representative
DEGs to validate the result of functional enrichment analysis, which was assessed 12 h after transfection of RA-FLSs with PlGF siRNA or control siRNA
(lower panel). A decrease in PlGF expression was confirmed in RA-FLSs by Western blot analysis after 24 h of transfection (upper panel). Data in the bar
graphs are the means and SD of three independent experiments. One-sample t test was applied to the fold induction. *p, 0.1, **p, 0.05, †p, 0.01 versus
RA-FLSs treated with control siRNA.
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containing PlGF-1 or PlGF-2 (Fig. 4C), indicating that soluble
PlGF promotes FLS survival. Moreover, after treatment of con-
ditioned media for PlGF-1 plus PlGF-2, pErk expression in RA-
FLSs rapidly increased, as early as 10 min and remained high up
to 12 h (Fig. 4D). In parallel, the expression of antiapoptotic Bcl2
increased, whereas proapoptotic Bax decreased 12 h after PlGF-1
plus PlGF-2 stimulation (Fig. 4D). Considering that FLSs secrete
PlGF by themselves, our data suggest that secreted PlGF-1 and
PlGF-2 promote the survival of RA-FLSs in an autocrine/
paracrine manner.
We have demonstrated that RA-FLSs express Flt-1 and NP-1, but
rarely KDR, on their surface (22). Additionally, PlGF selectively
binds Flt-1 and NP-1 (12, 14). Thus, we wanted to determine
whether PlGF by binding its receptors protects from FLS apo-
ptosis. To this end, we conducted a blocking experiment using
siRNA for Flt-1 or for NP-1. As shown in Fig. 4E, conditioned
media for PlGF-1 plus PlGF-2 reduced SNP-induced FLS apo-
ptosis, which was partially restored by the transfection of Flt-1
siRNA or NP-1 siRNA. Of note, cotransfection of Flt-1 siRNA
and NP-1 siRNA almost completely abrogated the PlGF protec-
tion from FLS apoptosis, implying that both receptors are required
for PlGF-1– and PlGF-2–dependent FLS survival.
Effects of PlGF on FLS migration and invasion
Invasiveness and increased migration are unique features of RA-
FLSs in addition to abnormal proliferation and apoptotic resis-
tance (10, 11). PlGF increases cell migration of some types of
cancer cells and myelomonocytic cells (12, 14). Finally, we tested
whether PlGF controls FLS migration and invasion. As shown in
Fig. 5A, under nonlethal time conditions (after 12 h), knockdown
of PlGF transcripts suppressed the wound migration of RA-FLSs
stimulated with 10% FBS. The IL-1b–induced increase in FLS
migration was also mitigated by PlGF siRNA. Furthermore, 10%
FBS- or IL-1b–stimulated invasion of RA-FLSs in a Matrigel
chamber was significantly blocked by transfection with PlGF
siRNA (Fig. 5B). Conversely, conditioned media containing PlGF-1
FIGURE 2. Effect of PlGF on FLS proliferation. (A and B) FLS proliferative responses to TNF-a and TGF-b. Twenty-four hours after transfection with
PlGF siRNA, RA-FLSs were treated with TGF-b (10 ng/ml) or TNF-a (10 ng/ml) for 72 h. The FLS proliferation rate was assessed by the BrdU in-
corporation assay (A) and trypan blue exclusion assay (B). Results are the means6 SD of three independent experiments performed in triplicate. *p, 0.05
versus control (scrambled) siRNA-transfected cells. (C) PlGF production by SV40-immortalized RA-FLSs transfected with the pCDNA3-hPlGF-1,
pCDNA3-hPlGF-2, or pCDNA3 vector only. PlGF concentrations in the culture supernatant were determined by ELISA. Data are the means 6 SD of five
independent experiments. *p , 0.05, **p , 0.01 versus vector-transfected cells. (D) Proliferation of SV40-immortalized RA-FLSs transfected with
pCDNA3-hPlGF-2 gene versus pCDNA3 vector. The cells (13 105) were cultured in serum-free media for 7 d. The number of cells was manually counted
every 2 d. *p , 0.05 versus vector-transfected cells. (E) H&E staining of Matrigels containing RA-FLSs implanted in immunodeficient mice (upper panel).
Scale bar, 500 mm. Prior to implantation, the expression of PlGF was determined in RA-FLSs by real-time PCR assay 7 d after transfection of PlGF siRNA
or control siRNA (lower panel). *p , 0.05 versus control siRNA-transfected cells. (F) Effect of PlGF siRNA on FLS proliferation in vivo. Matrigels
containing PlGF siRNA-transfected RA-FLSs plus TGF-b (50 ng/ml) were implanted into SCID mice. After 7 d, RA-FLSs in the Matrigels were identified
by immunofluorescence labeling for HLA class I Ag. Representative photographs of HLA+ cells are shown in green. Cells were manually counted under a
magnification of 3200. Scale bars, 100 mm. Values are the means 6 SD of four mice per group. *p , 0.05 versus control siRNA-transfected cells. (G)
Infiltrating mouse endothelial cells were stained using mouse anti-vWF Ab in the same Matrigels used for HLA staining. The cells positive for vWF are
shown in red. Scale bars, 100 mm. *p , 0.05 versus control siRNA-transfected cells.
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or PlGF-2 markedly increased FLS migration and invasion as
comparable to 10% FBS (Fig. 5C, 5D). These data showed that
PlGF was a positive regulator for migration and invasion of RA-
FLSs. Additionally, similar to FLS survival, the exogenous PlGF-1– or
PlGF-2–induced increase in FLS invasion was blocked by Flt-1
siRNA and/or NP-1 siRNA (Fig. 5E), indicating that both Flt-1 and
NP-1 were also required for PlGF-induced FLS invasion. Taken
together, these data suggest that PlGF promotes FLS invasion via
a receptor-coupling event.
Discussion
PlGF-1 and PlGF-2 isoforms may play different biochemical
functions in endothelial cells (12, 14). Interestingly, increased
PlGF-1 and PlGF-2 are of prognostic value in cancer patients (12,
14). PlGF is primarily secreted by FLSs in RA synovial tissue (6),
and its production can be induced by hypoxia (14, 37), cytokine
stimulation (14), and a cell-to-cell contact with mesenchymal stem
cells (14). Because RA joints are in a hypoxic condition, our recent
findings on involvement of HIF-1a in the upregulation of PlGF ex-
pression through chromatin remodeling is particularly relevant to RA
(37). In the present study, we identified that PlGF-1 and PlGF-2 are
the major PlGF isoforms in FLSs. Global gene expression profiling
revealed that a variety of pathologic processes, including cell pro-
liferation, apoptosis, angiogenesis, cytokine production, and cell
migration, were represented by the DEGs in RA-FLSs deficient of
PlGF transcripts. These results are indicative that PlGF is crucial to
RA pathogenesis via diverse pathologic processes.
The mechanisms by which normal cells acquire a transformed
phenotype have been an important issue in the pathogenesis of
human diseases. The uniquely transformed phenotype of FLSs in
FIGURE 3. Effect of PlGF on FLS survival. (A) Twelve hours after treatment of the cells with SNP (1 mM), photographs of RA-FLSs transfected with
PlGF siRNA or control siRNA were taken under phase-contrast microscopy. Scale bars, 100 mm. (B) Increase in FLS apoptosis by PlGF siRNA. FLS
apoptosis was induced by treatment with 1 mM SNP for 3 h or by serum starvation for 12 h. The degree of apoptosis was assessed by the APOPercentage
apoptosis assay, a colorimetric method, and is expressed as pixel numbers. Apoptotic cells appear bright pink. Results are the means 6 SD of three in-
dependent experiments performed in triplicate. Scale bars, 100 mm. *p , 0.05 versus control siRNA-transfected cells. (C) SV40-immortalized RA-FLSs
transfected with the pCDNA3-hPlGF-2 gene or pCDNA3 vector only were treated with 2.5 mM SNP for 24 h. Cell viability was determined by the MTT
assay. Data are expressed as the means 6 SD of six independent experiments in triplicate. *p , 0.05 versus untreated cells, †p , 0.05 versus vector only.
(D) The apoptosis of SV40-immortalized RA-FLSs harboring the pCDNA3-hPlGF-2 gene or pCDNA3 vector only was induced by serum starvation for
24 h or by treating cells with 1 mM SNP for 24 h. The degree of apoptosis was assessed by the APOPercentage assay. Data show means 6 SD of three
independent experiments in triplicate. Scale bars, 100 mm. *p , 0.05 versus vector only. (E) Expressions of pErk, total Erk, Bax, and Bcl-2 in RA-FLSs, as
determined by Western blot analysis. PlGF gene in RA-FLSs was downregulated by PlGF siRNA for 24 h (left panel) or upregulated by stable transfection
of pCDNA3-hPlGF-2 gene (right panel). Con siRNA, control siRNA. Data are representatives of three independent experiments with similar results. (F)
Effect of Erk inhibitor on apoptotic death of RA-FLSs. The hPlGF-2 overexpressed SV40-immortalized FLSs were incubated for 24 h with SNP (2.5 mM)
in the absence or presence of PD98059 (20 mM), an Erk inhibitor. The viability and survival of cells were determined by the MTT (left panel) and
APOPercentage assay (right panel), respectively. Data show means 6 SD of three independent experiments in triplicate. *p , 0.05 versus hPlGF-2–
overexpressed FLSs.
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RA has been associated with a genotoxic environment containing
reactive oxygen species, growth factors, and proinflammatory
cytokines (10). We clearly showed that PlGF is a critical regulator
of FLS proliferation by using PlGF-deficient and overexpressing
systems. Of note, TNF-a– or TGF-b–induced increases in FLS
proliferation were nearly completely blocked by PlGF siRNA. We
also confirmed that PlGF plays a role in TGF-b–stimulated FLS
proliferation in an in vivo xenotransplantation model. Overall, our
results suggest that PlGF mediates TNF-a– or TGF-b–induced
FLS proliferation, thus providing an explanation for the prolifer-
ative phenotype of primary rheumatoid cells.
Angiogenesis has been considered to be a critical step in the ini-
tiation and progression of chronic arthritis (2). It is upregulated by
many angiogenic factors, such as VEGF and PlGF. Indeed, PlGF may
directly stimulate vessel growth by directly promoting the growth,
migration, and survival of endothelial cells and also by increasing the
recruitment of smooth muscle cells and supporting the proliferation
of fibroblasts (12, 14). In the present study, knockdown of the PlGF
transcript in RA-FLSs significantly impeded the recruitment of en-
dothelial cells to Matrigel implants engrafted into immunodeficient
mice. These data, together with previous reports (6), suggest that
PlGF-mediated FLS proliferation increases production of angiogenic
factors, including VEGF and PlGF, by FLS themselves, and that this
indirectly contributes to neovascularization and pannus formation.
RA-associated changes in FLSs from normal to aggressive
behavior may be attributable to the upregulation of antiapoptotic
genes (10, 36). RA-FLSs abundantly express several antiapoptotic
proteins, including the FLICE inhibitory protein and Bcl2 (10, 36),
both of which protect against death receptor– or mitochondria-
dependent apoptotic pathways (36). We showed in the present
study that PlGF was essential to FLS survival. PlGF knockdown
resulted in increased apoptotic death of FLSs with Bcl2 downregu-
lation and Bax upregulation, whereas PlGF overexpression showed
the opposite results. Additionally, PlGF siRNA decreased pErk ac-
tivity, whereas PlGF overexpression enhanced it. Because pErk is
a well-known upstream regulator of Bcl2 (22, 36), and its inhibitor
(PD98059) restored SNP-induced apoptosis in PlGF-2–overex-
pressed RA-FLSs (Fig. 3F), PlGF promotes FLS survival by regu-
lating Bcl2/Bax expression possibly through the activation of pErk.
Taken together, our data suggest that chronic exposure of FLSs to
PlGF within the joints protects RA-FLSs from apoptosis, thereby
maintaining a unique hyperplastic phenotype.
PlGF activation of Flt-1 induces the Erk pathways (38). Because
RA-FLSs express Flt-1 and NP-1 on their surface (22), it is pos-
sible that secreted PlGF activates FLSs themselves in a paracrine/
autocrine manner by binding to Flt-1 and/or NP-1. However, the
direct role of the PlGF–Flt-1/NP-1 axis in synoviocyte pathology,
particularly the proliferative and invasive properties of RA-FLSs,
remains to be determined. The present study demonstrated that
both Flt-1 and NP-1 in RA-FLSs were required for signal trans-
duction of PlGF. Exogenous PlGF-1 and -2 rapidly triggered pErk
activity, increased Bcl2 over Bax expression, and prevented FLS
apoptosis. In contrast, PlGF-induced survival advantage was can-
celled by the addition of anti-PlGF Ab or siRNAs for both Flt-1
and NP-1. These findings indicate that the interaction of PlGF with
Flt-1/NP-1 enhances the survival of RA-FLSs in an autocrine/
paracrine manner. Our results offer a new possibility for PlGF re-
ceptors as potential targets for controlling FLS hyperplasia.
FIGURE 4. Exogenous PlGF increases
FLS survival via its receptors, Flt-1 and NP-1.
(A–C) Protection of RA-FLSs from apo-
ptotic death by exogenous PlGF. RA-FLSs
were treated with conditioned media con-
taining PlGF-1 (500 ng/ml) or PlGF-2 (500
ng/ml) for 3 h. FLS apoptosis was induced by
treating SNP (1 mM) for 6 h (A) or by serum
starvation for 12 h (B) in the absence or
presence of anti-PlGF Abs (100 mg/ml). FLS
apoptosis and viability were determined by
the APOPercentage (A and B) and MTT assay
(C), respectively. Data show means 6 SD of
three independent experiments in duplicate.
Scale bars, 50 mm. *p , 0.05 versus SNP or
serum starvation only. (D) RA-FLSs were
stimulated with conditioned media for
PlGF-1 (100 ng/ml) plus PlGF-2 (100 ng/ml)
for 10 min or 12 h. The expressions of pErk,
Bax, Bcl2, and pAkt were determined by
Western blot analysis. Data are representatives
of three independent experiments with similar
results. (E) Dependency of PlGF-induced sur-
vival on Flt-1 and NP-1 12 h after transfection
of siRNA for Flt-1, NP-1, or both. The RA-
FLSs were treated with SNP (1 mM) for 12 h
in the absence or presence of conditioned media
for PlGF-1 (100 ng/ml) plus PlGF-2 (100 ng/ml).
Cell viability was determined by the MTT assay.
Data show means 6 SD of three independent
experiments in triplicate. *p , 0.05 versus
SNP only.
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RA-FLSs actively participate in cartilage/bone destruction by
releasing matrix degrading enzymes, such as matrix metallo-
proteinase. They can be detached from hyperplastic synoviums and
then migrate to and invade adjacent structures without the help of
other immune cells (10, 11). RA-FLSs can spread disease by
migrating from affected to distant unaffected joints in immune-
deficient mice (11). In this regard, antimigratory agents targeting
RA-FLSs may thus be of therapeutic benefit. For example, treat-
ment targeting cadherin-11, which is selectively expressed on
FLSs, prevents arthritis in mouse models (39). In the present
study, we found that PlGF siRNA hampered media or IL-1b–
stimulated migration and invasion of RA-FLSs. Conversely, the
ligation of PlGF-1 (or PlGF-2) to its receptors (Flt1-1/NP-1)
promoted such processes, suggesting that the PlGF–Flt-1/NP-1
axis is essential for RA-FLSs to maintain a promigratory and in-
vasive phenotype.
RA synovial tissues can be viewed as a tumor-like mass con-
sisting of hyperplastic FLSs and surrounding inflammatory cells (1,
4). Given that current therapeutic agents targeting T cells, B cells,
and cytokines show a limited success, RA-FLSs are an attractive
target to achieve complete remission. In this study, we demon-
strated that PlGF-1 and -2 were positive regulators for abnormal
proliferation, apoptotic resistance, excessive migration, and inva-
sion of RA-FLSs beyond their role for neovascularization. These
results provided evidence on how primary cells of mesenchymal
origin acquire an aggressive and transformed phenotype. The
blockade of PlGF and its receptors could be a novel strategy to
target the deleterious functions of RA-FLSs.
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FIGURE 5. Exogenous PlGF increases FLS migration and invasion via its receptors, Flt-1 and NP-1. (A) Effects of PlGF siRNA on wound migration of
RA-FLSs. After 12 h of transfection with PlGF siRNA or control siRNA (Con siRNA), RA-FLSs were incubated in DMEM containing 10% FBS or IL-1b
(10 ng/ml) plus 1% FBS for 12 h. Cells migrating beyond the reference line were photographed and counted. Data show the means 6 SD of three in-
dependent experiments. Scale bars, 200 mm. *p , 0.05. (B) RA-FLS invasion in a Matrigel chamber, as determined at 12 h after transfection of PlGF
siRNA versus control siRNA. Invaded cells were stained violet using Diff-Quik kit. Results are the means 6 SD of three independent experiments. Scale
bars, 200 mm. *p , 0.05 versus control siRNA (Con siRNA). (C and D) Increases in wound migration and invasion of FLSs by exogenous PlGF. Under
serum-free conditions, RA-FLSs were incubated with conditioned media containing PlGF-1 (100 ng/ml) or PlGF-2 (100 ng/ml) for 12 h. The migrated cells
in a wound area (C) and invaded cells in a Matrigel chamber (D) were manually counted. FBS (10%) was used as a positive control. Data show means6 SD
of three independent experiments in duplicate. Scale bars, 200 mm. *p, 0.05 versus serum-free media. (E) Reduction of RA-FLS invasion by Flt-1 or NP-1
siRNA. After 12 h of transfection with Flt-1, NP-1, or both, RA-FLSs were incubated in conditioned media for PlGF-1 (100 ng/ml) or PlGF-2 (100 ng/ml)
12 h. Results are the means 6 SD of three independent experiments. Scale bars, 100 mm. *p , 0.05 versus control siRNA (Con siRNA)–transfected cells.
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